Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea

Journal of Dermatological Treatment

Volumn 19, Issue 5, 2008, Pages 267-273

  Jayawant, Sujata S ^a   Feldman, Steven R ^b   Camacho, Fabian T ^c   Yentzer, Brad ^b   Balkrishnan, Rajesh ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Healthcare costs; Metronidazole; Refill adherence; Rosacea

Indexed keywords

ADAPALENE; AZELAIC ACID; METRONIDAZOLE; PERMETHRIN; SULFACETAMIDE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CHILD; CONTROLLED STUDY; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; ROSACEA; SENSITIVITY ANALYSIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; MALE; MEDICAID; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; ROSACEA; UNITED STATES; YOUNG ADULT;

EID: 51049112669     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630801955176     Document Type: Article

References (29)

1. Facts about rosacea. Accessed: November 8, 2007. URL: http://www.niams.nih.gov/Health_Info/Rosacea/default.asp.
2. Jansen T, Plewig G. Rosacea: Classification and treatment. J R Soc Med. 1997;90:144-50.
3. Kligman AM. A personal critique on the state of knowledge of rosacea. Dermatology. 2004;208:191-7.
4. Crawford GH, Pelle MT, James WD. Rosacea, I: Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-41.
5. Willkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-7.
6. Willkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard grading system for rosacea: Report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-12.
7. Michel JL, Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea [French]. Ann Dermatol Venereol. 2003;130:20-4.
8. National Rosacea Society, Accessed: November 8, 2007. URL: http://www.rosacea.org/index.php.
9. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
10. Nally JB, Berson DS. Topical therapies for rosacea. J Drugs Dermatol. 2006;5:23-6.
11. Zuber TJ. Rosacea. Prim Care. 2000;27:309-18.
12. Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: A possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282:449-54.
13. Gnarpe H, Belsheim J, Persson S. Influence of nitroimidazole derivatives on leukocyte migration. Scand J Infect Dis Suppl. 1981;26:68-71.
14. Persi A, Rebora A. Metronidazole and Demodex folliculorum. Acta Derm Venereol. 1981;61:182-3.
15. Wolf JE Jr. The role of topical metronidazole in the treatment of rosacea. Cutis. 2004;73(suppl I):19-28.
16. Van Zuuren E, Graber MA, Hollis S, Chaudhry M, Gupta AK. Interventions for rosacea. Cochrane Database Syst Rev. 2004;1:CD003262.
17. Del Rosso JQ. A status report on medical management of rosacea: Focus on topical therapies. Cutis. 2002;70:271-5.
18. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
19. Caroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-16.
20. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004;4:191-5.
21. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: A healthcare problem. Ann Pharmacother. 1993;27:S1-24.
22. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24:512-57.
23. Wolf JE, Jr. Medication adherence: A key factor in effective management of rosacea. Adv Ther. 2001;18:272-81.
24. Centers for Medicare and Medicaid services; Table of contents for the state of NC. Accessed: November 1, 2007. URL: http://www.cms.hss.gov/medicaid/ stateplans/toc.asp?state=.
25. Halvorsen R, Palmquist R. The interpretation of dummy variables in semilogarithmic equations. Am Econ Rev. 1980;70:474-5.
26. Kennedy P. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev. 1981;71:801.
27. Habif TP. Clinical dermatology: A color guide to diagnosis and therapy. St Louis: Mosby, 1996. p. 182-3.
28. Blount WB, Pelletier AL. Rosacea: A common, yet overlooked condition. Am Fam Physician. 2002;66:435-40.
29. Willkin JK. Rosacea: Pathophysiology and treatment [Editorial]. Arch Dermatol. 1999;130:359-62.